Storia in 4 fonti

Supernus, Indivior to merge and form CNS-focused drugmaker

Supernus and Indivior agree to an all-stock merger creating a $2.2B CNS biopharma led by CEO Jack Khattar, closing Q4 2026.

Raccontata da

Confronto fonti

4 prospettive sulla stessa storia

AI · summaries

endpoints.newsStai leggendo18 h fa

Supernus, Indivior to merge and form CNS-focused drugmaker

Supernus and Indivior agree to an all-stock merger creating a $2.2B CNS biopharma led by CEO Jack Khattar, closing Q4 2026.

originale

benzinga.com15 h fa

Supernus to Combine with Indivior To Form CNS Biopharmaceutical Leader with Potential $2 Billion in Reven

Supernus and Indivior merge as equals to form $2.2B CNS pharma leader with $125M annual cost synergies. Leverage <1x enables strategic M&A pursuit in psychiatry/neurology/addiction markets where AI diagnosis trends are reshaping treatment.

Leggi questa versione → originale

Timeline cronologica

lunedì 3 agosto 2026·biopharmadive.com
Supernus, Individor merge to beef up brain drug portfolio
The transaction combines two companies marketing nearly a dozen neurological drugs that bring in steady, but not blockbuster sales for conditions such as opioid use disorder and…
lunedì 3 agosto 2026·endpoints.news
Supernus, Indivior to merge and form CNS-focused drugmaker
Supernus and Indivior agree to an all-stock merger creating a $2.2B CNS biopharma led by CEO Jack Khattar, closing Q4 2026.

Supernus, Indivior to merge and form CNS-focused drugmaker

Confronto fonti

Supernus, Indivior to merge and form CNS-focused drugmaker

Supernus to Combine with Indivior To Form CNS Biopharmaceutical Leader with Potential $2 Billion in Reven

Timeline cronologica

Supernus, Individor merge to beef up brain drug portfolio

Supernus, Indivior to merge and form CNS-focused drugmaker

Supernus, Indivior merge to create CNS-focused company and expand BD opportunities

Supernus, Individor merge to beef up brain drug portfolio

Supernus to Combine with Indivior To Form CNS Biopharmaceutical Leader with Potential $2 Billion in Reven

Supernus, Indivior merge to create CNS-focused company and expand BD opportunities